Why do patients quit a key lung cancer drug? new study aims to find out
NCT ID NCT07542210
First seen Apr 22, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study interviews about 85 lung cancer patients and 15 doctors to learn what helps or hinders patients from continuing a targeted pill called osimertinib after surgery. The goal is to identify barriers like side effects, costs, or communication issues, and facilitators like support from family or doctors. Findings may help improve long-term treatment adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Beijing, China
Conditions
Explore the condition pages connected to this study.